AbbVie and Xilio Partner to Develop Next-Gen Immunotherapies

AbbVie and Xilio Therapeutics have announced a strategic collaboration to advance tumor-activated immunotherapies, including innovative masked T-cell engagers. Xilio’s proprietary platform technology enables selective activation of biologics within the tumor microenvironment, aiming to enhance efficacy while minimizing systemic side effects. This partnership aligns with AbbVie's commitment to developing next-generation oncology treatments that improve patient outcomes.

As part of the agreement, Xilio will receive $52 million in upfront payments, including a $10 million equity investment, with the potential for up to $2.1 billion in milestone payments and tiered royalties. Industry leaders from both companies expressed enthusiasm about leveraging their combined expertise in protein engineering and oncology research to push the boundaries of cancer immunotherapy.